Terms: = Prostate cancer AND KLK2, P20151, 3817, ENSG00000167751, MGC12201, hK2, KLK2A2 AND Clinical Outcome
3 results:
1. GLUT1 expression in high-risk prostate cancer: correlation with
Meziou S; Ringuette Goulet C; Hovington H; Lefebvre V; Lavallée É; Bergeron M; Brisson H; Champagne A; Neveu B; Lacombe D; Beauregard JM; Buteau FA; Riopel J; Pouliot F
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):441-448. PubMed ID: 31932660
[TBL] [Abstract] [Full Text] [Related]
2. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved clinical outcome.
GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
[TBL] [Abstract] [Full Text] [Related]
3. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.
Avgeris M; Mavridis K; Scorilas A
Biol Chem; 2012 Apr; 393(5):301-17. PubMed ID: 22505514
[TBL] [Abstract] [Full Text] [Related]
